Ultragenyx Pharmaceutical RARE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $136M-34.4% | $207.28M+29.6% | $159.93M-3.9% | $166.5M+19.8% | $139M-15.6% | ||
| $187M-8.0% | $203.28M-6.0% | $216.21M+31.2% | $164.74M-0.8% | $166M-11.7% | ||
| $88M+0.1% | $87.94M+1.5% | $86.62M0.0% | $86.65M-0.4% | $87M+6.2% | ||
| -$169M-49.2% | -$113.28M+33.7% | -$170.89M-58.4% | -$107.89M+24.6% | -$143M-16.9% | ||
| -124.3%-69.6pp | -54.7%+52.2pp | -106.9%-42.1pp | -64.8%+38.1pp | -102.9%-28.6pp | ||
| $6M-7.9% | $6.51M+11.1% | $5.86M+1.2% | $5.79M-17.2% | $7M-30.3% | ||
| -$184M-44.1% | -$127.69M+28.9% | -$179.54M-57.5% | -$114M+24.0% | -$150M-12.9% | ||
| $1M+14.9% | $870K-0.3% | $873K-7.8% | $947K-5.3% | $1M+160% | ||
| -$185M-43.9% | -$128.56M+28.7% | -$180.41M-56.9% | -$114.95M+23.9% | -$151M-13.4% | ||
| -136%-74.0pp | -62%+50.8pp | -112.8%-43.8pp | -69%+39.6pp | -108.6%-27.7pp | ||
| -$1.84-43.7% | -$1.28+29.3% | -$1.81-54.7% | -$1.17+25.5% | -$1.57-13.8% | ||
| -$1.84-43.7% | -$1.28+29.3% | -$1.81-54.7% | -$1.17+25.5% | -$1.57-13.8% | ||
| 100.6M+2.0% | 98.6M-1.2% | 99.8M+1.3% | 98.5M+2.2% | 96.3M+6.4% | ||
| 100.6M+2.0% | 98.6M-1.2% | 99.8M+1.3% | 98.5M+2.2% | 96.3M+6.4% | ||
| $30M+2.2% | $29.35M+4.8% | $27.99M+21.7% | $23M-20.7% | $29M+68.9% | ||
| $305M-4.9% | $320.56M-3.1% | $330.82M+20.6% | $274.38M-2.7% | $282M-1.7% | ||
| $21M+7.9% | $19.47M+37.6% | $14.15M+0.8% | $14.04M+0.3% | $14M-9.6% | ||
| $136M-34.4% | $207.28M+29.6% | $159.93M-3.9% | $166.5M+19.8% | $139M-15.6% | ||
| -$169M-49.2% | -$113.28M+33.7% | -$170.89M-58.4% | -$107.89M+24.6% | -$143M-16.9% | ||
| -$161M-54.1% | -$104.5M+35.6% | -$162.28M-63.5% | -$99.28M+25.9% | -$134M-18.8% | ||
| -$161M-54.1% | -$104.5M+35.6% | -$162.28M-63.5% | -$99.28M+25.9% | -$134M-18.8% | ||
| -118.4%-68.0pp | -50.4%+51.1pp | -101.5%-41.8pp | -59.6%+36.8pp | -96.4%-27.9pp | ||
| -$169M-49.2% | -$113.28M+33.7% | -$170.89M-58.4% | -$107.89M+24.6% | -$143M-16.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ultragenyx Pharmaceutical's profit margins?
- Gross margin is 97.2% and operating margin is -83.8%, with a -90.9% net margin.
- Where does Ultragenyx Pharmaceutical's income statement data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.